Cargando…

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35%

BACKGROUND: Consensus guidelines support the use of implanted cardioverter-defibrillators (ICD) for primary prevention of sudden cardiac death in patients with either non-ischaemic or ischaemic cardiomyopathy with left ventricular ejection fraction (LVEF) ≤35%. However, evidence from trials for effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wasfy, Jason H, Achanta, Aditya, Hidrue, Michael K, Urbut, Sarah, Axtell, Andrea L, Berman, Adam N, Zhao, Yunong, Chen, Julian, Gustus, Sarah, Picard, Michael H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Heart Failure and Cardiomyopathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462974/ https://www.ncbi.nlm.nih.gov/pubmed/37625819 http://dx.doi.org/10.1136/openhrt-2023-002289

Ejemplares similares

Implantable cardioverter defibrillator deactivation and advance care planning: a focus group study
por: Stoevelaar, Rik, et al.
Publicado: (2020)

Role of N-terminal pro-B type natriuretic peptide as a predictor of poor outcomes in patients with HFrEF receiving primary prevention implantable cardioverter-defibrillator therapy: a systematic review and dose–response meta-analysis
por: Prameswari, Hawani Sasmaya, et al.
Publicado: (2023)

Exploring the acceptability of implantable defibrillators in patients with cardiac dystrophinopathy and carers
por: Hiermeier, Ursula M, et al.
Publicado: (2020)

Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification
por: Cubbon, Richard M, et al.
Publicado: (2016)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

Developing a contemporary community clinic for patients with heart failure with preserved ejection fraction within the current National Health Service model
por: Tran, Patrick, et al.
Publicado: (2022)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Beale, Anna L, et al.
Publicado: (2019)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

Diastolic index as a short-term prognostic factor in heart failure with preserved ejection fraction
por: Hoshida, Shiro, et al.
Publicado: (2020)

Association of early versus delayed normalisation of left ventricular ejection fraction with mortality in ischemic cardiomyopathy
por: Schiffer, Walter B, et al.
Publicado: (2021)

Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review
por: Zheng, Sean L, et al.
Publicado: (2016)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Zheng, Sean Lee, et al.
Publicado: (2018)

Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia
por: Abohammar, Samah, et al.
Publicado: (2017)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
por: Ganesananthan, Sashiananthan, et al.
Publicado: (2020)

Development of algorithms for determining heart failure with reduced and preserved ejection fraction using nationwide electronic healthcare records in the UK
por: Sundaram, Varun, et al.
Publicado: (2022)

Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model
por: Sotomi, Yohei, et al.
Publicado: (2023)

Extracellular cardiac matrix biomarkers in patients with reduced ejection fraction heart failure as predictors of response to cardiac resynchronisation therapy: a systematic review
por: McAloon, Christopher J, et al.
Publicado: (2017)

Non-invasive intraventricular pressure differences estimated with cardiac MRI in subjects without heart failure and with heart failure with reduced and preserved ejection fraction
por: Londono-Hoyos, Francisco, et al.
Publicado: (2019)

Prognostic value of left ventricular mitral annular longitudinal displacement obtained by tissue Doppler imaging in patients with heart failure with reduced ejection fraction
por: Sengeløv, Morten, et al.
Publicado: (2021)

Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study
por: Abboud, Andrew, et al.
Publicado: (2021)

Colchicine in patients with heart failure and preserved left ventricular ejection fraction: rationale and design of a prospective, randomised, open-label, crossover clinical trial
por: Shchendrygina, Anastasia, et al.
Publicado: (2023)

Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials
por: Suebsaicharoen, Thanakit, et al.
Publicado: (2023)

Rationale and design of the NEO-NORMAL-AF study examination of the usefulness of implantable loop recorder for arrhythmia detection including atrial fibrillation in heart failure with non-reduced ejection fraction cases: a pilot study
por: Sugiura, Junichi, et al.
Publicado: (2023)

Association between right ventricular strain and outcomes in patients with dilated cardiomyopathy
por: Liu, Tong, et al.
Publicado: (2021)

Discrepancy between left ventricular hypertrophy by echocardiography and electrocardiographic hypertrophy: clinical characteristics and outcomes
por: Seko, Yuta, et al.
Publicado: (2021)

SOCIODEMOGRAPHIC DIFFERENCES IN THE UTILIZATION OF REMOTE PULMONARY ARTERY PRESSURE MEASUREMENTS FOR HEART FAILURE PATIENTS IN THE USA
por: Markson, Favour, et al.
Publicado: (2023)

Associations between left bundle branch block with different PR intervals, QRS durations, heart rates and the risk of heart failure: a register-based cohort study using ECG data from the primary care setting
por: Søndergaard, Marc Meller, et al.
Publicado: (2021)

Pathophysiology of exercise intolerance in chronic diseases: the role of diminished cardiac performance in mitochondrial and heart failure patients
por: McCoy, Jodi, et al.
Publicado: (2017)

Body composition and risk of heart failure: protocol for a systematic review and meta-analysis
por: Oguntade, Ayodipupo S., et al.
Publicado: (2021)

Habitual physical activity levels of adults with heart failure: systematic review and meta-analysis
por: Jordan, Cara, et al.
Publicado: (2023)

Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004–2018
por: Taylor, Clare J, et al.
Publicado: (2022)

OUTCOMES IN THE OUTPATIENT MANAGEMENT OF HEART FAILURE PATIENTS DURING THE COVID-19 PANDEMIC AFTER ROBUST ADOPTION OF A TELEHEALTH MODEL
por: Sammour, Yasser, et al.
Publicado: (2021)

Characteristics and outcome of patients with COVID-19 complicated by Takotsubo cardiomyopathy: case series with literature review
por: Hegde, Shruti, et al.
Publicado: (2020)

From randomised controlled trial to real world implementation of a novel home-based heart failure tool: pooled and comparative analyses of two clinical controlled trials
por: Hovland-Tånneryd, Ann, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ch3sjn6fcemf8nia98q9gi7vvd